LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis
Figure 2.LncRNA ADAMTS9-AS2 acted as a RNA sponge to regulate miR-223-3p in GC cells. (A) The targeting sites of LncRNA ADAMTS9-AS2 and miR-223-3p were predicted by using the online starBase software (http://starbase.sysu.edu.cn). Dual-luciferase reporter gene system was used to verify the binding sites in (B) SGC7901 cells and (C) BGC-823 cells, respectively. (D) RIP was performed to measure the binding abilities of LncRNA ADAMTS9-AS2 and miR-223-3p. Real-Time qPCR was used to examine the expression levels of (E) LncRNA ADAMTS9-AS2 and (F) miR-223-3p in GC cells. Each experiment repeated at least 3 times. “NS” represented “no statistical significance”, *P < 0.05, **P < 0.01.